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ABSTRACT 
More than 80% of women who are diagnosed with cancer before the age of 40 will survive long-
term. As a result, there are nearly 400,000 reproductive-aged women who have a history of 
cancer and cancer treatment in the United States. Due to cancer treatment, these young cancer 
survivors face higher risks for shortened reproductive lifespans, infertility, and primary ovarian 
insufficiency. Therefore, estimating their remaining ovarian reserve is important to identify 
potential opportunities for biologic parenthood. Anti-mullerian hormone (AMH) is a 
glycoprotein produced by early staged ovarian follicles in women and can be used as a sensitive 
biomarker of ovarian reserve. It has been shown that pre-chemotherapy AMH levels can predict 
post-chemotherapy ovarian function, making AMH a promising clinical tool for measuring 
residual ovarian function after cancer. However, logistics and costs of venipuncture blood 
collection associated with AMH testing have limited our ability to further explore this topic on a 
large scale in young adult cancer survivors. We have conducted a pilot study in which young 
adult cancer survivors were asked to collect dried blood spot samples by themselves. My project 
aims to characterize the feasibility of DBS self collection for measuring AMH in this population. 
BACKGROUND 
As a result of the advancement in cancer treatment, more than 80% of young girls and women 
who are diagnosed with cancer before the age of 40 will survive long-term.1 Consequently, there 
are nearly 400,000 reproductive-aged women who have a history of cancer and cancer treatment 
in the United States. It is known that cancer treatments such as chemotherapy, radiation, and 
endocrine therapy, can have long-term negative effects on a woman’s reproductive health. These 
late effects of therapy include shortened reproductive lifespans, infertility, and primary ovarian 
insufficiency that result in a lower overall quality of life.2,3,4 Because most young cancer 
survivors (YCS) will have some residual ovarian function after cancer treatment, estimating their 
remaining ovarian reserve important to identify potential opportunities for biologic parenthood.5  
Ovarian reserve is a term that is used to describe the ability of an ovary to produce a healthy 
mature follicle for fertilization and conception. Ovarian reserve tests (ORT) are used to help 
determine a women’s reproductive potential based on the quality and/or quantity of their 
remaining oocytes.6 There are several different ORTs that can determine ovarian reserve. Current 
literature suggests that anti-mullerian hormone (AMH) blood concentrations may be the most 
sensitive biomarker for ovarian reserve compared to follicle stimulating hormone (FSH), 
estradiol (E2), antral follicle count (AFC), or Inhibin B.7   
AMH is a glycoprotein hormone that plays a large role in sexual differentiation in utero as well 
as ovarian functioning in reproductive-aged women.8,9 In adulthood, AMH is exclusively 
produced by granulosa cells in the ovarian follicles. AMH production is highest in the preantral 
and small antral stages of follicle development. AMH production stops before the follicle 
matures into a tertiary follicle. Because AMH production occurs only in the early stages of 
follicle development, blood levels of AMH can be used to estimate the size of the primordial 
oocyte pool in women. AMH levels peak at puberty and begin to decline at age 25, reaching 
undetectable levels around 40 years old.10 
In the context of cancer, AMH levels can help identify ovarian function in young survivors. First, 
periodic assessment of AMH levels can help physicians identify impact of chemotherapeutic 
agents on ovarian reserve.11 Second, AMH levels can help determine remaining ovarian function 
after successful completion of cancer treatment.12 In addition, pre-chemotherapy AMH levels 
predict post-chemotherapy ovarian function.13 For these reasons, AMH is a promising marker for 
measuring the residual window of ovarian function after cancer. However, this area of research 
has been limited by small sample sizes due to the costs and logistics associated with 
venipuncture blood collection.14  
Dried blood spots (DBS) provide a more cost-effective and feasible alternative for AMH testing. 
DBS is a novel approach that collects drops of whole blood on filter paper following a simple 
finger prick.15 Recent validation work has demonstrated that assays for quantifying AMH in 
DBS samples are highly sensitive and reliable.16 While DBS collections have successfully been 
performed in large health surveys and/or by trained individuals including healthcare providers 
and research assistants, self-collected DBSS, has not been described.17 If successful, self-
collected DBS would facilitate larger sample collections from YCS who are geographically 
diverse. The objectives of this study is to 1) determine the feasibility of obtaining self-collected 
DBS to measure ovarian reserve in a large, geographically diverse population of female YCS and 
2) to characterize the association of self-collected DBS AMH levels with participant
characteristics and exposures.
DEFINITIONS 
What are the goals of the project? 
The general goals of this project are to: 
• Better understand fertility and ovarian function issues that occur in young female cancer
survivors
• Participate in data cleaning, data analysis and manuscript preparation
• Build connections with leading researchers in this area of research
The specific goals of this project are to: 
• Characterize the feasibility of self collection for DBS in this population
• Clean primary data
• Learn to use statistical software (STATA or SPSS)
• Analyze primary data: summarize descriptive data, conduct bivariable and multivariable
analyses to examine factors associated with DBS-measured AMH levels
• Gain expertise in various AMH assays in order to make appropriate conclusions from lab
data
What is innovative about the project? 
By expanding our knowledge on the implications of using DBS for measuring AMH levels, we 
are searching for more feasible and cost-effective ways to assess ovarian reserve in a very 
vulnerable population (young cancer survivors). AMH blood levels are commonly used in 
infertility clinics to predict time to pregnancy, patient management with in vitro fertilization, and 
ovarian reserve. However, many of these patients present with infertility issues unrelated to 
cancer treatment. It is known that AMH levels and fecundity decrease during chemotherapy and 
typically continue to stay low 3-6 months after cancer treatment. However, there is a paucity of 
studies using AMH to define the long-term effects of cancer treatment on ovarian reserve. This 
project aims to provide an innovative method for measuring AMH. We will test to see if self-
collected DBS is a feasible tool for studying ovarian reserve in geographically diverse female 
young cancer survivors. If so, this may provide a better opportunity at conducting large sample 
size, longitudinal studies of ovarian reserve in YCS.  
 
How is the project relevant to a career in medicine? 
Being diagnosed with cancer is very physically and emotionally detrimental. Because of this, I 
find it particularly important to empower women who have cancer with options that may allow 
them to have healthy families of their own in the future. As an aspiring OBGYN, this project is 
especially relevant to my personal career choice in medicine because it focuses on alternative 
ways to address female infertility. By learning the various etiologies for decreased fertility as 
well as the methods used to characterize a women’s reproductive capacity, I hope to be one step 
closer to becoming the kind of physician I wish to be.  
 
What is the student’s role in and time commitment to the project? 
I will complete the bulk of the data collection, analysis, and write up during the summer of my 
first year (approximately 40 hours/week from June 29th to Sept 10th). In the first 2 weeks, I will 
actively engage in literature research to be up-to-date on the research topic, I will take online 
tutorials to familiarize myself with STATA or SPSS.  With my mentor, I will formulate an 
analysis plan.  Then, I will conduct the analysis in parallel with the team’s statistician to learn the 
skills relevant for this study. By the end of the summer, I will work alongside my immediate 
supervisors and ISP Chair to write up the results of this study. The paper submission process will 
most likely extend into MS2 fall quarter. 
 
METHODS 
Study population: 
From 2011 to 2013, 295 participants were recruited from the Fertility Information Research 
Study (FIRST). FIRST is an ongoing prospective cohort study assessing reproductive health in 
young cancer survivors. Participants were included in the study if they were female, ages 18 to 
44, and had a history of cancer or exposure to cancer treatment. This participant pool was invited 
to participate in a pilot study on using dried blood spots to measure ovarian reserve. Interested 
survivors were invited to hear about the DBS study in full, after which they provided consent for 
participation.  
 
DBS Collection: 
Each consented participant was mailed a study packet that included: an instructional brochure for 
DBS collection, 2 lancets, a blood spot collection card with 5 DBS circles, various biohazard 
safety tools, a brief questionnaire on current hormone use and recent menstrual cycle, and a 
return envelope. Once received, DBS samples were frozen at -80C. 
 
AMH measurements: 
AMH will be measured using the picoAMH assay.  Ansh Laboratory (Texas) will conduct the 
assays. DBS standards, samples and controls will be removed from the -80C freezer the day 
before the assay. Samples will be analyzed for AMH concentration by quantitative, three-step 
sandwich ELISA immunoassay (Ansh Labs #AL-129). From the DBS collection card, 3.2 mm 
discs will be punched out and placed in 12X75 culture tubes for elution in extraction buffer. 
Assays will be run with single spot and corrected for spot dilution.  
 
Statstical analysis 
 
Returned AMH levels will be analyzed using SAS statistical software. Categorical variables will 
be summarized by frequency and proportion. Continuous variable will be summarized by means, 
medians, and range. Baseline characteristics of FIRST participants will be compared by DBS 
study enrollment using Fisher’s Exact or Student’s t-test, as appropriate. AMH levels will be log-
transformed to approximate a normal distribution. Analysis of variance will be used to compare 
AMH levels by participant characteristics. Two-tailed p-values <0.05 will be considered 
significant. 
 
EVALUATION 
I will have accomplished the above goals and successful completed the project if I meet the 
following criteria: 
• Was able to gain the necessary statistical skills to analyze AMH data for the purpose of 
associating AMH levels with participant characteristics and exposures 
• Gained enough knowledge about AMH, DBS, and ovarian reserve in vulnerable 
populations, like young cancer survivors, to make reasonable clinical suggestions for the 
utility of AMH testing 
• Contribute significantly to the publication of this project 
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